A Phase 3 interventional study of 13 valent Pneumococcal Conjugate Vaccine and 13 valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccines, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 6 sites in United States. Open to participants aged 60 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-07-22.
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of this study is to compare the safety, tolerability and immunologic response to a dose of 23vPS or 13vPnC given one year after either 13vPnC or 23vPS in subjects that have never received a previous dose of 23vPS.
Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.
First submitted before Wyeth became part of Pfizer.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Group 1.1 = 13vPnC then 13vPnC
Biological: 13 valent Pneumococcal Conjugate Vaccine
Group 1.2 = 13vPnC then 23vPS
Biological: 13 valent Pneumococcal Conjugate Vaccine · Biological: 23-valent Pneumococcal Polysaccharide Vaccine
Group 2 = 23vPS then 13vPnC
Biological: 13 valent Pneumococcal Conjugate Vaccine · Biological: 23-valent Pneumococcal Polysaccharide Vaccine
0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and year 1
0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and 0.5 ml dose 23vPS at year 1
0.5 ml dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5 ml dose 13vPnC at year 1
0.5 ml dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5 ml dose 13vPnC at year 1
0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and 0.5 ml dose 23vPS at year 1
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 23vPS (Year 1) Versus 23vPS (Year 0)
Antibody geometric mean titers as measured by opsonophagocytic assays (OPA) for 12 common pneumococcal serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
Time frame: 1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 23vPS Versus 23vPS / 13vPnC (Year 1)
Antibody geometric mean titers as measured by opsonophagocytic assays (OPA) for 12 common pneumococcal serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
Time frame: 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes for 13vPnC / 13vPnC (Year 1) Versus 13vPnC (Year 0)
Antibody geometric mean titers as measured by opsonophagocytic assays (OPA) for the pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). The 6A pneumococcal serotype is specific to 13vPnC. Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
Time frame: 1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 23vPS (Year 1) Versus 13vPnC (Year 0)
Antibody geometric mean titers as measured by opsonophagocytic assays (OPA) for 12 common pneumococcal serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
Time frame: 1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 23vPS / 13vPnC (Year 1) Versus 13vPnC (Year 0)
Antibody geometric mean titers as measured by opsonophagocytic assays (OPA) for 12 common pneumococcal serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
Time frame: 1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 1 (Year 0) 13vPnC and 23vPS
Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters \[cm\]; Moderate (5.1 to 10.0 cm); Severe (\>10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating); Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).
Time frame: 14 days after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 14 days after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1)
Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters \[cm\]; Moderate (5.1 to 10.0 cm); Severe (\>10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating); Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).
Time frame: 14 days after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 14 days after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 13vPnC (Year 0) and 23vPS / 13vPnC (Year 1)
Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters \[cm\]; Moderate (5.1 to 10.0 cm); Severe (\>10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating); Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).
Time frame: 14 days after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 14 days after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 23vPS (Year 0) and 13vPnC / 23vPS (Year 1)
Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters \[cm\]); Moderate (5.1 to 10.0 cm); Severe (\>10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating); Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).
Time frame: 14 days after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 14 days after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 2 (Year 1) 13vPnC / 13vPnC, 13vPnC / 23vPS, and 23vPS / 13vPnC
Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters \[cm\]; Moderate (5.1 to 10.0 cm); Severe (\>10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating); Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).
Time frame: 14 days after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 1 (Year 0) 13vPnC and 23vPS
Systemic events reported using an electronic diary. Systemic events are any fever ≥38 degrees Celsius \[C\], fatigue, headache, chills, rash, vomiting, decreased appetite, new generalized muscle pain (new muscle pain), aggravated generalized muscle pain (aggravated muscle pain), new generalized joint pain (new joint pain), and aggravated generalized joint pain (aggravated joint pain). Participants may be represented in more than 1 category.
Time frame: 14 days after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1])
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 13vPnC (Year 0) and 13vPnC / 13vPnC (Year 1)
Systemic events reported using an electronic diary. Systemic events are any fever ≥38 degrees Celsius \[C\], fatigue, headache, chills, rash, vomiting, decreased appetite, new generalized muscle pain (new muscle pain), aggravated generalized muscle pain (aggravated muscle pain), new generalized joint pain (new joint pain), and aggravated generalized joint pain (aggravated joint pain). Participants may be represented in more than 1 category.
Time frame: 14 days after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 14 days after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 13vPnC (Year 0) and 23vPS / 13vPnC (Year 1)
Systemic events reported using an electronic diary. Systemic events are any fever ≥38 degrees Celsius \[C\], fatigue, headache, chills, rash, vomiting, decreased appetite, new generalized muscle pain (new muscle pain), aggravated generalized muscle pain (aggravated muscle pain), new generalized joint pain (new joint pain), and aggravated generalized joint pain (aggravated joint pain). Participants may be represented in more than 1 category.
Time frame: 14 days after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 14 days after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 23vPS (Year 0) and 13vPnC / 23vPS (Year 1)
Systemic events reported using an electronic diary. Systemic events are any fever ≥38 degrees Celsius \[C\], fatigue, headache, chills, rash, vomiting, decreased appetite, new generalized muscle pain (new muscle pain), aggravated generalized muscle pain (aggravated muscle pain), new generalized joint pain (new joint pain), and aggravated generalized joint pain (aggravated joint pain). Participants may be represented in more than 1 category.
Time frame: 14 days after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 14 days after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 2 (Year 1) 13vPnC / 13vPnC, 13vPnC / 23vPS, and 23vPS / 13vPnC
Systemic events reported using an electronic diary. Systemic events are any fever ≥38 degrees Celsius \[C\], fatigue, headache, chills, rash, vomiting, decreased appetite, new generalized muscle pain (new muscle pain), aggravated generalized muscle pain (aggravated muscle pain), new generalized joint pain (new joint pain), and aggravated generalized joint pain (aggravated joint pain). Participants may be represented in more than 1 category.
Time frame: 14 days after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)
| Milestone | 13vPnC - Group 1.1 or 1.2 | 23vPS - Group 2 |
|---|---|---|
| Started | 482 | 238 |
| Received vaccination 1 (vax 1) | 478 | 237 |
| Completed vax 1 (6 month contact) | 468 | 234 |
| Withdrawn after vax 1 (6 month contact) | 7 | 3 |
| Withdrawn before vax 2 | 41 | 11 |
| Received vax 2 | 427 | 223 |
| Completed vax 2 (6 month contact) | 421 | 222 |
| Completed | 421 | 222 |
| Not completed | 61 | 16 |
Antibody geometric mean titers as measured by opsonophagocytic assays (OPA) for 12 common pneumococcal serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
| geometric mean titer | 13vPnC / 23vPS | 23vPS |
|---|---|---|
| Common Serotype 1 | 148 (123.7 to 176.5) | 148 (117.9 to 185.9) |
| Common Serotype 3 | 125 (108.6 to 143.4) | 80 (67.5 to 95.7) |
| Common Serotype 4 | 1385 (1171.2 to 1638.7) | 1357 (1023.0 to 1799.0) |
| Common Serotype 5 | 199 (161.4 to 246.2) | 140 (107.0 to 183.5) |
| Common Serotype 6B | 1215 (965.4 to 1528.3) | 706 (522.1 to 954.0) |
| Common Serotype 7F | 537 (422.4 to 682.6) | 331 (233.5 to 469.1) |
| Common Serotype 9V | 373 (268.4 to 517.6) | 288 (198.0 to 419.1) |
| Common Serotype 14 | 622 (485.7 to 796.4) | 734 (543.6 to 990.1) |
| Common Serotype 18C | 1062 (863.2 to 1307.6) | 789 (586.2 to 1062.2) |
| Common Serotype 19A | 467 (403.5 to 541.0) | 376 (302.8 to 465.7) |
| Common Serotype 19F | 774 (642.0 to 933.6) | 509 (385.5 to 672.9) |
| Common Serotype 23F | 198 (151.2 to 259.4) | 70 (49.9 to 97.3) |
Antibody geometric mean titers as measured by opsonophagocytic assays (OPA) for 12 common pneumococcal serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
| geometric mean titer | 13vPnC / 23vPS | 23vPS / 13vPnC |
|---|---|---|
| Common Serotype 1 | 148 (123.7 to 176.5) | 77 (60.7 to 98.1) |
| Common Serotype 3 | 125 (108.6 to 143.4) | 50 (40.9 to 61.7) |
| Common Serotype 4 | 1385 (1171.2 to 1638.7) | 935 (739.9 to 1182.4) |
| Common Serotype 5 | 199 (161.4 to 246.2) | 85 (64.2 to 112.0) |
| Common Serotype 6B | 1215 (965.4 to 1528.3) | 710 (529.1 to 953.2) |
| Common Serotype 7F | 537 (422.4 to 682.6) | 126 (85.6 to 184.6) |
| Common Serotype 9V | 373 (268.4 to 517.6) | 114 (76.5 to 169.3) |
| Common Serotype 14 | 622 (485.7 to 796.4) | 435 (323.0 to 585.7) |
| Common Serotype 18C | 1062 (863.2 to 1307.6) | 564 (418.2 to 761.7) |
| Common Serotype 19A | 467 (403.5 to 541.0) | 289 (235.7 to 353.9) |
| Common Serotype 19F | 774 (642.0 to 933.6) | 286 (217.3 to 376.7) |
| Common Serotype 23F | 198 (151.2 to 259.4) | 124 (88.2 to 173.0) |
Antibody geometric mean titers as measured by opsonophagocytic assays (OPA) for the pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). The 6A pneumococcal serotype is specific to 13vPnC. Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
| geometric mean titer | 13vPnC Vaccination 1 (Year 0) | 13vPnC / 13vPnC Vaccination 2 (Year 1) |
|---|---|---|
| Common Serotype 1 | 215 (163.9 to 282.4) | 142 (112.2 to 180.4) |
| Common Serotype 3 | 73 (57.2 to 94.1) | 89 (75.2 to 105.4) |
| Common Serotype 4 | 2255 (1625.2 to 3128.6) | 1214 (931.8 to 1582.1) |
| Common Serotype 5 | 170 (112.1 to 258.6) | 98 (69.6 to 136.6) |
| Additional Serotype 6A | 2682 (1969.5 to 3652.1) | 2281 (1747.1 to 2978.5) |
| Common Serotype 6B | 2112 (1508.0 to 2958.2) | 1882 (1429.7 to 2477.9) |
| Common Serotype 7F | 930 (602.1 to 1437.1) | 323 (215.8 to 482.8) |
| Common Serotype 9V | 919 (619.1 to 1364.0) | 335 (214.6 to 522.6) |
| Common Serotype 14 | 492 (312.7 to 774.5) | 384 (262.4 to 561.2) |
| Common Serotype 18C | 1440 (1015.3 to 2043.5) | 986 (730.8 to 1330.2) |
| Common Serotype 19A | 583 (426.6 to 796.8) | 385 (308.2 to 481.6) |
| Common Serotype 19F | 566 (385.7 to 829.2) | 502 (381.3 to 662.1) |
| Common Serotype 23F | 291 (187.7 to 452.2) | 456 (322.4 to 644.7) |
Antibody geometric mean titers as measured by opsonophagocytic assays (OPA) for 12 common pneumococcal serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
| geometric mean titer | 13vPnC Vaccination 1 (Year 0) | 13vPnC / 23vPS Vaccination 2 (Year 1) |
|---|---|---|
| Common Serotype 1 | 220 (178.9 to 269.3) | 140 (117.4 to 168.1) |
| Common Serotype 3 | 74 (61.3 to 88.7) | 129 (112.4 to 147.5) |
| Common Serotype 4 | 2517 (2091.7 to 3029.2) | 1430 (1214.7 to 1683.9) |
| Common Serotype 5 | 227 (170.9 to 300.5) | 188 (151.1 to 234.8) |
| Common Serotype 6B | 2012 (1571.9 to 2574.1) | 1351 (1087.6 to 1677.0) |
| Common Serotype 7F | 1252 (971.1 to 1614.4) | 533 (419.2 to 678.2) |
| Common Serotype 9V | 758 (563.8 to 1018.9) | 406 (292.3 to 564.6) |
| Common Serotype 14 | 664 (485.1 to 908.5) | 616 (473.3 to 802.2) |
| Common Serotype 18C | 1532 (1183.7 to 1982.7) | 1074 (871.7 to 1322.2) |
| Common Serotype 19A | 696 (581.1 to 833.6) | 457 (389.5 to 536.3) |
| Common Serotype 19F | 696 (546.3 to 887.7) | 773 (636.6 to 937.6) |
| Common Serotype 23F | 358 (265.5 to 481.7) | 216 (165.0 to 282.7) |
Antibody geometric mean titers as measured by opsonophagocytic assays (OPA) for 12 common pneumococcal serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
| geometric mean titer | 13vPnC | 23vPS / 13vPnC |
|---|---|---|
| Common Serotype 1 | 207 (177.7 to 240.9) | 77 (60.7 to 98.1) |
| Common Serotype 3 | 75 (66.0 to 85.3) | 50 (40.9 to 61.7) |
| Common Serotype 4 | 2536 (2192.3 to 2933.0) | 935 (739.9 to 1182.4) |
| Common Serotype 5 | 215 (175.9 to 261.7) | 85 (64.2 to 112.0) |
| Common Serotype 6B | 1948 (1614.0 to 2351.7) | 710 (529.1 to 953.2) |
| Common Serotype 7F | 1063 (868.6 to 1302.2) | 126 (85.6 to 184.6) |
| Common Serotype 9V | 767 (620.0 to 949.3) | 114 (76.5 to 169.3) |
| Common Serotype 14 | 650 (524.9 to 805.8) | 435 (323.0 to 585.7) |
| Common Serotype 18C | 1576 (1321.3 to 1880.9) | 564 (418.2 to 761.7) |
| Common Serotype 19A | 709 (618.9 to 811.2) | 289 (235.7 to 353.9) |
| Common Serotype 19F | 711 (595.9 to 848.9) | 286 (217.3 to 376.7) |
| Common Serotype 23F | 354 (283.8 to 440.7) | 124 (88.2 to 173.0) |
Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters \[cm\]; Moderate (5.1 to 10.0 cm); Severe (\>10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating); Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).
| percentage of participants | 13vPnC | 23vPS |
|---|---|---|
| Redness: Any (n=270, 134) | 12.2 | 11.2 |
| Redness: Mild (n=266, 134) | 8.3 | 9.7 |
| Redness: Moderate (n=264, 128) | 6.4 | 3.9 |
| Redness: Severe (n=259, 127) | 1.2 | 0.8 |
| Swelling: Any (n=270, 135) | 10.0 | 10.4 |
| Swelling: Mild (n=268, 132) | 8.2 | 6.1 |
| Swelling: Moderate (n=263, 132) | 3.8 | 7.6 |
| Swelling: Severe (n=258, 127) | 0.0 | 0.0 |
| Pain: Any (n=370, 175) | 69.2 | 58.3 |
| Pain: Mild (n=360, 170) | 66.1 | 52.9 |
| Pain: Moderate (n=284, 143) | 20.1 | 21.7 |
| Pain: Severe (n=261, 127) | 2.3 | 0.8 |
| Limitation of arm movement: Any (n=289, 142) | 23.5 | 28.2 |
| Limitation of arm movement: Mild (n=286, 142) | 22.7 | 26.1 |
| Limitation of arm movement: Moderate (n=260, 127) | 1.2 | 3.1 |
| Limitation of arm movement: Severe (n=261, 128) | 1.1 | 2.3 |
Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters \[cm\]; Moderate (5.1 to 10.0 cm); Severe (\>10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating); Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).
| percentage of participants | 13vPnC | 13vPnC / 13vPnC |
|---|---|---|
| Redness: Any (n=61, 61) | 14.8 | 11.5 |
| Redness: Mild (n=57, 57) | 7.0 | 8.8 |
| Redness: Moderate (n=58, 58) | 8.6 | 3.4 |
| Redness: Severe (n=57, 57) | 0.0 | 3.5 |
| Swelling: Any (n=60, 60) | 10.0 | 11.7 |
| Swelling: Mild (n=59, 59) | 6.8 | 8.5 |
| Swelling: Moderate (n=55, 55) | 1.8 | 3.6 |
| Swelling: Severe (n=56, 56) | 0.0 | 1.8 |
| Pain: Any (n=108, 108) | 76.9 | 75.9 |
| Pain: Mild (n=101, 101) | 72.3 | 72.3 |
| Pain: Moderate (n=61, 61) | 21.3 | 26.2 |
| Pain: Severe (n=57, 57) | 0.0 | 3.5 |
| Limitation of arm movement: Any (n=65, 65) | 26.2 | 24.6 |
| Limitation of arm movement: Mild (n=65, 65) | 26.2 | 24.6 |
| Limitation of arm movement: Moderate (n=56, 56) | 1.8 | 0.0 |
| Limitation of arm movement: Severe (n=56, 56) | 0.0 | 1.8 |
Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters \[cm\]; Moderate (5.1 to 10.0 cm); Severe (\>10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating); Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).
| percentage of participants | 13vPnC | 23vPS / 13vPnC |
|---|---|---|
| Redness: Any (n=270, 115) | 12.2 | 4.3 |
| Redness: Mild (n=266, 115) | 8.3 | 4.3 |
| Redness: Moderate (n=264, 115) | 6.4 | 0.9 |
| Redness: Severe (n=259, 115) | 1.2 | 0.0 |
| Swelling: Any (n=270, 119) | 10.0 | 5.0 |
| Swelling: Mild (n=268, 119) | 8.2 | 5.0 |
| Swelling: Moderate (n=263, 116) | 3.8 | 0.9 |
| Swelling: Severe (n=258, 115) | 0.0 | 0.0 |
| Pain: Any (n=370, 169) | 69.2 | 69.8 |
| Pain: Mild (n=360, 166) | 66.1 | 68.1 |
| Pain: Moderate (n=284, 129) | 20.1 | 17.8 |
| Pain: Severe (n=261, 116) | 2.3 | 0.9 |
| Limitation of arm movement: Any (n=289, 130) | 23.5 | 18.5 |
| Limitation of arm movement: Mild (n=286, 130) | 22.7 | 16.9 |
| Limitation of arm movement: Moderate (n=260, 115) | 1.2 | 0.0 |
| Limitation of arm movement: Severe (n=261, 115) | 1.1 | 1.7 |
Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters \[cm\]); Moderate (5.1 to 10.0 cm); Severe (\>10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating); Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).
| percentage of participants | 23vPS | 13vPnC / 23vPS |
|---|---|---|
| Redness: Any (n=134, 151) | 11.2 | 27.8 |
| Redness: Mild (n=134, 144) | 9.7 | 19.4 |
| Redness: Moderate (n=128, 138) | 3.9 | 12.3 |
| Redness: Severe (n=127, 131) | 0.8 | 6.9 |
| Swelling: Any (n=135, 155) | 10.4 | 25.8 |
| Swelling: Mild (n=132, 149) | 6.1 | 20.1 |
| Swelling: Moderate (n=132, 138) | 7.6 | 12.3 |
| Swelling: Severe (n=127, 132) | 0.0 | 6.1 |
| Pain: Any (n=175, 231) | 58.3 | 85.7 |
| Pain: Mild (n=170, 205) | 52.9 | 78.5 |
| Pain: Moderate (n=143, 176) | 21.7 | 49.4 |
| Pain: Severe (n=127, 140) | 0.8 | 12.9 |
| Limitation of arm movement: Any (n=142, 178) | 28.2 | 53.4 |
| Limitation of arm movement: Mild (n=142, 171) | 26.1 | 47.4 |
| Limitation of arm movement: Moderate (n=127, 134) | 3.1 | 10.4 |
| Limitation of arm movement: Severe (n=128, 135) | 2.3 | 8.1 |
Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters \[cm\]; Moderate (5.1 to 10.0 cm); Severe (\>10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating); Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).
| percentage of participants | 13vPnC / 13vPnC | 13vPnC / 23vPS | 23vPS / 13vPnC |
|---|---|---|---|
| Redness: Any (n=86, 151, 115) | 12.8 | 27.8 | 4.3 |
| Redness: Mild (n=83, 144, 115) | 7.2 | 19.4 | 4.3 |
| Redness: Moderate (n=83, 138, 115) | 7.2 | 12.3 | 0.9 |
| Redness: Severe (n=83, 131, 115) | 2.4 | 6.9 | 0.0 |
| Swelling: Any (n=86, 155, 119) | 14.0 | 25.8 | 5.0 |
| Swelling: Mild (n=85, 149, 119) | 10.6 | 20.1 | 5.0 |
| Swelling: Moderate (n=82, 138, 116) | 6.1 | 12.3 | 0.9 |
| Swelling: Severe (n=82, 132, 115) | 1.2 | 6.1 | 0.0 |
| Pain: Any (n=129, 231, 169) | 75.2 | 85.7 | 69.8 |
| Pain: Mild (n=123, 205, 166) | 72.4 | 78.5 | 68.1 |
| Pain: Moderate (n=91, 176, 129) | 24.2 | 49.4 | 17.8 |
| Pain: Severe (n=83, 140, 116) | 2.4 | 12.9 | 0.9 |
| Limitation of arm movement: Any (n=93, 178, 130) | 28.0 | 53.4 | 18.5 |
| Limitation of arm movement: Mild (n=92, 171, 130) | 27.2 | 47.4 | 16.9 |
| Limitation of arm movement: Moderate(n=83,134,115) | 3.6 | 10.4 | 0.0 |
| Limitation of arm movement: Severe (n=82, 135,115) | 1.2 | 8.1 | 1.7 |
Systemic events reported using an electronic diary. Systemic events are any fever ≥38 degrees Celsius \[C\], fatigue, headache, chills, rash, vomiting, decreased appetite, new generalized muscle pain (new muscle pain), aggravated generalized muscle pain (aggravated muscle pain), new generalized joint pain (new joint pain), and aggravated generalized joint pain (aggravated joint pain). Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC | 23vPS |
|---|---|---|
| Fever: Any ≥38 degrees C (n=263, 127) | 4.6 | 1.6 |
| Fever: Mild ≥38 but <38.5 degrees C (n=263, 127) | 3.8 | 0.8 |
| Fever: Moderate ≥38.5 but <39 degrees C(n=259,127) | 0.8 | 0.0 |
| Fever: Severe ≥39 but ≤40 degrees C (n=259, 127) | 0.4 | 0.8 |
| Fever Potentially life threatening >40C(n=258,127) | 0.4 | 0.0 |
| Fatigue (n=321, 173) | 50.5 | 49.1 |
| Headache (n=328, 167) | 49.7 | 46.1 |
| Chills (n=286, 145) | 19.9 | 26.9 |
| Rash (n=267, 134) | 8.6 | 13.4 |
| Vomiting (n=261, 131) | 3.1 | 3.1 |
| Decreased appetite (n=278, 148) | 14.7 | 23.0 |
| New muscle pain (n=324, 167) | 46.9 | 51.5 |
| Aggravated muscle pain (n=286, 154) | 22.0 | 32.5 |
| New joint pain (n=278, 147) | 15.5 | 23.81 |
| Aggravated joint pain (n=272, 142) | 14.0 | 21.1 |
Systemic events reported using an electronic diary. Systemic events are any fever ≥38 degrees Celsius \[C\], fatigue, headache, chills, rash, vomiting, decreased appetite, new generalized muscle pain (new muscle pain), aggravated generalized muscle pain (aggravated muscle pain), new generalized joint pain (new joint pain), and aggravated generalized joint pain (aggravated joint pain). Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC | 13vPnC / 13vPnC |
|---|---|---|
| Fever: Any ≥38 degrees C (n=55, 55) | 9.1 | 3.6 |
| Fever: Mild ≥38 but <38.5 degrees C (n=55, 55) | 7.3 | 0.0 |
| Fever: Moderate ≥38.5 but <39 degrees C(n=55, 55) | 0.0 | 1.8 |
| Fever: Severe ≥39 but ≤40 degrees C (n=55, 55) | 0.0 | 0.0 |
| Fever Potentially life threatening >40C (n=55, 55) | 1.8 | 1.8 |
| Fatigue (n=76, 76) | 56.6 | 43.4 |
| Headache (n=76, 76) | 52.6 | 44.7 |
| Chills (n=61, 61) | 18.0 | 19.7 |
| Rash (n=60, 60) | 8.3 | 10.0 |
| Vomiting (n=56, 56) | 7.1 | 3.6 |
| Decreased appetite (n=61, 61) | 13.1 | 21.3 |
| New muscle pain (n=84, 84) | 47.6 | 51.2 |
| Aggravated muscle pain (n=68, 68) | 26.5 | 30.9 |
| New joint pain (n=62, 62) | 14.5 | 16.1 |
| Aggravated joint pain (n=62, 62) | 16.1 | 19.4 |
Systemic events reported using an electronic diary. Systemic events are any fever ≥38 degrees Celsius \[C\], fatigue, headache, chills, rash, vomiting, decreased appetite, new generalized muscle pain (new muscle pain), aggravated generalized muscle pain (aggravated muscle pain), new generalized joint pain (new joint pain), and aggravated generalized joint pain (aggravated joint pain). Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC | 23vPS / 13vPnC |
|---|---|---|
| Fever: Any ≥38 degrees C (n=263, 116) | 4.6 | 0.9 |
| Fever: Mild ≥38 but <38.5 degrees C (n=263, 116) | 3.8 | 0.9 |
| Fever: Moderate ≥38.5 but <39 degrees C(n=259,115) | 0.8 | 0.0 |
| Fever: Severe ≥39 but ≤40 degrees C(n=259,115) | 0.4 | 0.0 |
| Fever Potentially life threatening >40C(n=258,115) | 0.4 | 0.0 |
| Fatigue (n=321, 141) | 50.5 | 41.1 |
| Headache (n=328, 139) | 49.7 | 40.3 |
| Chills (n=286, 127) | 19.9 | 19.7 |
| Rash (n=267, 121) | 8.6 | 8.3 |
| Vomiting (n=261, 118) | 3.1 | 6.8 |
| Decreased appetite (n=278, 123) | 14.7 | 13.0 |
| New muscle pain (n=324, 151) | 46.9 | 45.0 |
| Aggravated muscle pain (n=286, 136) | 22.0 | 28.7 |
| New joint pain (n=278, 128) | 15.5 | 19.5 |
| Aggravated joint pain (n=272, 131) | 14.0 | 21.4 |
Systemic events reported using an electronic diary. Systemic events are any fever ≥38 degrees Celsius \[C\], fatigue, headache, chills, rash, vomiting, decreased appetite, new generalized muscle pain (new muscle pain), aggravated generalized muscle pain (aggravated muscle pain), new generalized joint pain (new joint pain), and aggravated generalized joint pain (aggravated joint pain). Participants may be represented in more than 1 category.
| percentage of participants | 23vPS | 13vPnC / 23vPS |
|---|---|---|
| Fever: Any ≥38 degrees C (n=127, 129) | 1.6 | 3.1 |
| Fever: Mild ≥38 but <38.5 degrees C (n=127, 129) | 0.8 | 3.1 |
| Fever: Moderate ≥38.5 but <39 degrees C(n=127,127) | 0.0 | 0.0 |
| Fever: Severe ≥39 but ≤40 degrees C(n=127,127) | 0.8 | 0.0 |
| Fever Potentially life threatening >40C(n=127,127) | 0.0 | 0.0 |
| Fatigue (n=173, 185) | 49.1 | 51.9 |
| Headache (n=167, 175) | 46.1 | 49.7 |
| Chills (n=145, 155) | 26.9 | 29.0 |
| Rash (n=134, 146) | 13.4 | 24.0 |
| Vomiting (n=131, 131) | 3.1 | 4.6 |
| Decreased appetite (n=148, 141) | 23.0 | 17.0 |
| New muscle pain (n=167, 196) | 51.5 | 61.2 |
| Aggravated muscle pain (n=154, 164) | 32.5 | 41.5 |
| New joint pain (n=147, 153) | 23.8 | 25.5 |
| Aggravated joint pain (n=142, 143) | 21.1 | 17.5 |
Systemic events reported using an electronic diary. Systemic events are any fever ≥38 degrees Celsius \[C\], fatigue, headache, chills, rash, vomiting, decreased appetite, new generalized muscle pain (new muscle pain), aggravated generalized muscle pain (aggravated muscle pain), new generalized joint pain (new joint pain), and aggravated generalized joint pain (aggravated joint pain). Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC / 13vPnC | 13vPnC / 23vPS | 23vPS / 13vPnC |
|---|---|---|---|
| Fever: Any ≥38 degrees C (n=81, 129, 116) | 2.5 | 3.1 | 0.9 |
| Fever: Mild ≥38 but <38.5 degrees C (n=81,129,116) | 0.0 | 3.1 | 0.9 |
| Fever: Moderate ≥38.5, <39 degrees C(n=81,127,115) | 1.2 | 0.0 | 0.0 |
| Fever: Severe ≥39, ≤40 degrees C(n=81,127,115) | 0.0 | 0.0 | 0.0 |
| Potentially life threatening >40C(n=81,127,115) | 1.2 | 0.0 | 0.0 |
| Fatigue (n=100, 185, 141) | 39.0 | 51.9 | 41.1 |
| Headache (n=96, 175, 139) | 41.7 | 49.7 | 40.3 |
| Chills (n=90, 155, 127) | 18.9 | 29.0 | 19.7 |
| Rash (n=86, 146, 121) | 10.5 | 24.0 | 8.3 |
| Vomiting (n=82, 131, 118) | 3.7 | 4.6 | 6.8 |
| Decreased appetite (n=89, 141, 123) | 18.0 | 17.0 | 13.0 |
| New muscle pain (n=108, 196, 151) | 50.0 | 61.2 | 45.0 |
| Aggravated muscle pain (n=94, 164, 136) | 26.6 | 41.5 | 28.7 |
| New joint pain (n=87, 153, 128) | 14.9 | 25.5 | 19.5 |
| Aggravated joint pain (n=91, 143, 131) | 17.6 | 17.5 | 21.4 |
Collected over Informed consent through 6 Month Follow-up after last vaccination. Local reactions and systemic events assessed within 14 days after vaccination 1 (Vax 1=Day 1/Year 0 [Visit 1]) and 14 days after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 13vPnC (Year 0) | — | 2/478 (0.4%) | 256/478 (53.6%) |
| 23vPS (Year 0) | — | 1/237 (0.4%) | 102/237 (43%) |
| 13vPnC: 6 Month Follow-up After Vax 1 (Year 0) | — | 15/478 (3.1%) | 41/478 (8.6%) |
| 23vPS: 6 Month Follow-up After Vax 1 (Year 0) | — | 6/237 (2.5%) | 24/237 (10.1%) |
| 13vPnC / 13vPnC (Year 1) | — | 0/160 (0%) | 97/160 (60.6%) |
| 13vPnC / 23vPS (Year 1) | — | 2/267 (0.7%) | 198/267 (74.2%) |
| 23vPS / 13vPnC (Year 1) | — | 1/223 (0.4%) | 118/223 (52.9%) |
| 13vPnC / 13vPnC: 6 Month Follow-up After Vax 2 (Year 1) | — | 5/160 (3.1%) | 16/160 (10%) |
| 13vPnC / 23vPS: 6 Month Follow-up After Vax 2 (Year 1) | — | 6/267 (2.2%) | 23/267 (8.6%) |
| 23vPS / 13vPnC: 6 Month Follow-up After Vax 2 (Year 1) | — | 3/223 (1.3%) | 16/223 (7.2%) |
| Event | 13vPnC (Year 0) | 23vPS (Year 0) | 13vPnC: 6 Month Follow-up After Vax 1 (Year 0) | 23vPS: 6 Month Follow-up After Vax 1 (Year 0) | 13vPnC / 13vPnC (Year 1) | 13vPnC / 23vPS (Year 1) | 23vPS / 13vPnC (Year 1) | 13vPnC / 13vPnC: 6 Month Follow-up After Vax 2 (Year 1) | 13vPnC / 23vPS: 6 Month Follow-up After Vax 2 (Year 1) | 23vPS / 13vPnC: 6 Month Follow-up After Vax 2 (Year 1) |
|---|---|---|---|---|---|---|---|---|---|---|
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/478 | 0/237 | 0/478 | 1/237 | 0/160 | 1/267 | 1/223 | 2/160 | 0/267 | 0/223 |
| Foot fractureInjury, poisoning and procedural complications | 0/478 | 0/237 | 0/478 | 0/237 | 0/160 | 0/267 | 0/223 | 1/160 | 0/267 | 0/223 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/478 | 0/237 | 1/478 | 0/237 | 0/160 | 0/267 | 0/223 | 1/160 | 0/267 | 0/223 |
| Uterine cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/478 | 0/237 | 0/478 | 0/237 | 0/160 | 0/267 | 0/223 | 1/160 | 0/267 | 0/223 |
| Coronary artery diseaseCardiac disorders | 0/478 | 0/237 | 0/478 | 0/237 | 0/160 | 0/267 | 0/223 | 0/160 | 0/267 | 1/223 |
| Small intestinal obstructionGastrointestinal disorders | 0/478 | 0/237 | 0/478 | 0/237 | 0/160 | 0/267 | 0/223 | 0/160 | 1/267 | 1/223 |
| Non-cardiac chest painGeneral disorders | 0/478 | 0/237 | 0/478 | 1/237 | 0/160 | 0/267 | 0/223 | 0/160 | 1/267 | 1/223 |
| Accidental overdoseInjury, poisoning and procedural complications | 0/478 | 0/237 | 0/478 | 0/237 | 0/160 | 0/267 | 0/223 | 0/160 | 0/267 | 1/223 |
| Benign neoplasm of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/478 | 0/237 | 0/478 | 0/237 | 0/160 | 0/267 | 0/223 | 0/160 | 0/267 | 1/223 |
| Angina unstableCardiac disorders | 0/478 | 1/237 | 0/478 | 0/237 | 0/160 | 0/267 | 0/223 | 0/160 | 0/267 | 0/223 |
| Event | 13vPnC (Year 0) | 23vPS (Year 0) | 13vPnC: 6 Month Follow-up After Vax 1 (Year 0) | 23vPS: 6 Month Follow-up After Vax 1 (Year 0) | 13vPnC / 13vPnC (Year 1) | 13vPnC / 23vPS (Year 1) | 23vPS / 13vPnC (Year 1) | 13vPnC / 13vPnC: 6 Month Follow-up After Vax 2 (Year 1) | 13vPnC / 23vPS: 6 Month Follow-up After Vax 2 (Year 1) | 23vPS / 13vPnC: 6 Month Follow-up After Vax 2 (Year 1) |
|---|---|---|---|---|---|---|---|---|---|---|
| Pain (Any)Skin and subcutaneous tissue disorders | — | 102/175 | — | — | — | 198/231 | — | — | — | — |
| Pain (Any)Skin and subcutaneous tissue disorders | — | — | — | — | 97/129 | 198/231 | 118/169 | — | — | — |
| Pain (Mild)Skin and subcutaneous tissue disorders | — | 90/170 | — | — | — | 161/205 | — | — | — | — |
| Pain (Mild)Skin and subcutaneous tissue disorders | — | — | — | — | 89/123 | 161/205 | 113/166 | — | — | — |
| Pain (Any)Skin and subcutaneous tissue disorders | 83/108 | — | — | — | 82/108 | — | — | — | — | — |
| Pain (Mild)Skin and subcutaneous tissue disorders | 73/101 | — | — | — | 73/101 | — | — | — | — | — |
| Pain (Any)Skin and subcutaneous tissue disorders | 256/370 | — | — | — | — | — | 118/169 | — | — | — |
| Pain (Any)Skin and subcutaneous tissue disorders | 256/370 | 102/175 | — | — | — | — | — | — | — | — |
| Pain (Mild)Skin and subcutaneous tissue disorders | 238/360 | — | — | — | — | — | 113/166 | — | — | — |
| Pain (Mild)Skin and subcutaneous tissue disorders | 238/360 | 90/170 | — | — | — | — | — | — | — | — |
| Age Continuous(years) | 13vPnC - Group 1.1 or 1.2 | 23vPS - Group 2 | Total |
|---|---|---|---|
| Mean | 61.7 ± 1.4 | 61.7 ± 1.4 | 61.7 ± 1.4 |
| Sex: Female, Male(Participants) | 13vPnC - Group 1.1 or 1.2 | 23vPS - Group 2 | Total |
|---|---|---|---|
| Female | 281 | 134 | 415 |
| Male | 197 | 103 | 300 |
The record gives a start of Nov 2007, a primary completion of Feb 2010 and a completion of Feb 2010. It does not say whether these dates are actual or estimated.
Results were first posted in May 2011, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine
Wyeth is now a wholly owned subsidiary of Pfizer →